Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunomodulatory drugs in multiple myeloma: Impact of the SCARMET (Self CARe and MEdication Toxicity) educational intervention on outpatients' knowledge to manage adverse effects.
Périchou J, Ranchon F, Herledan C, Huot L, Larbre V, Carpentier I, Lazareth A, Karlin L, Beny K, Vantard N, Schwiertz V, Caffin AG, Baudouin A, Sesques P, Brisou G, Ghesquières H, Salles G, Rioufol C. Périchou J, et al. Among authors: rioufol c. PLoS One. 2020 Dec 4;15(12):e0243309. doi: 10.1371/journal.pone.0243309. eCollection 2020. PLoS One. 2020. PMID: 33275634 Free PMC article. Clinical Trial.
Predictors of prescription errors involving anticancer chemotherapy agents.
Ranchon F, Moch C, You B, Salles G, Schwiertz V, Vantard N, Franchon E, Dussart C, Henin E, Colomban O, Girard P, Freyer G, Rioufol C. Ranchon F, et al. Among authors: rioufol c. Eur J Cancer. 2012 May;48(8):1192-9. doi: 10.1016/j.ejca.2011.12.031. Epub 2012 Jan 28. Eur J Cancer. 2012. PMID: 22285178
Hypersensitivity to oxaliplatin: clinical features and risk factors.
Parel M, Ranchon F, Nosbaum A, You B, Vantard N, Schwiertz V, Gourc C, Gauthier N, Guedat MG, He S, Kiouris E, Alloux C, Vial T, Trillet-Lenoir V, Freyer G, Berard F, Rioufol C. Parel M, et al. Among authors: rioufol c. BMC Pharmacol Toxicol. 2014 Jan 13;15:1. doi: 10.1186/2050-6511-15-1. BMC Pharmacol Toxicol. 2014. PMID: 24417770 Free PMC article.
ELLIPSE Study: a Phase 1 study evaluating the tolerance of bevacizumab nasal spray in the treatment of epistaxis in hereditary hemorrhagic telangiectasia.
Dupuis-Girod S, Ambrun A, Decullier E, Samson G, Roux A, Fargeton AE, Rioufol C, Schwiertz V, Disant F, Chapuis F, Donazzolo Y, Paintaud G, Edery P, Faure F. Dupuis-Girod S, et al. Among authors: rioufol c. MAbs. 2014 May-Jun;6(3):794-9. doi: 10.4161/mabs.28025. Epub 2014 Jan 30. MAbs. 2014. PMID: 24481211 Free PMC article. Clinical Trial.
Administration of anticancer drugs: exposure in hospital nurses.
Rioufol C, Ranchon F, Schwiertz V, Vantard N, Joue E, Gourc C, Gauthier N, Guedat MG, Salles G, Souquet PJ, Favier B, Gilles L, Freyer G, You B, Trillet-Lenoir V, Guitton J. Rioufol C, et al. Clin Ther. 2014 Mar 1;36(3):401-7. doi: 10.1016/j.clinthera.2014.01.016. Epub 2014 Mar 5. Clin Ther. 2014. PMID: 24612942
Obinutuzumab for chronic lymphocytic leukemia.
Rioufol C, Salles G. Rioufol C, et al. Expert Rev Hematol. 2014 Oct;7(5):533-43. doi: 10.1586/17474086.2014.953478. Epub 2014 Aug 28. Expert Rev Hematol. 2014. PMID: 25163491
96 results